- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05960331
Influence of Autonomy on Motor Learning in People With Parkinson's Disease
November 16, 2025 updated by: National Taiwan University Hospital
The goal of this clinical trial is to explore the benefits of autonomy supported learning in patients with Parkinson's disease. The main questions to answer are:
- Whether autonomy supported learning can benefit motor learning in PD patients
- Whether autonomy supported learning can enhance intrinsic motivation and/ or information processing of PD patients in learning a new task.
- Whether autonomy supported learning can facilitate cortical excitability change after practicing a new task.
Participants will be recruited into two groups (Self-control group, SC; and yoked group, YK) to learn a finger-pressing trajectory matching task
- Participants in SC group will have choice over feedback schedule during trial practice
- Participants in YK group will receive feedback with no-choice during trial practice Researchers will compare the retention test performance to see if autonomy supported learning will lead to better learning effect.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Autonomy is the sense of learner to actively participate in determining their own behaviour.
The present study aims to investigate whether an autonomy supported practice (with self-controlled feedback) would benefit adults with Parkinson's disease (PD), along with increased intrinsic motivation, information processing and cortical excitability.
Two groups of healthy adults and two groups of PD patients will be recruited to learn a finger-pressing trajectory matching task.
Participants will be allocated in either a self-control group (choice over feedback schedule), or a yoked group (receive feedback with no-choice).
Learning will be assessed on the second day and one week later, along with an error estimation of learners' own performance to represent their information processing ability.
Cortical excitability and inhibition will be assessed via transcranial magnetic stimulation as indicators of cortical plasticity.
Questionnaire regarding motivation will be assessed before and after practice trials.
Study hypothesized that individual with PD would benefit from autonomy supported learning, with better performance, enhanced motivation and information processing, associates with change of cortical excitability
Study Type
Interventional
Enrollment (Estimated)
72
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ya-Yun Lee, PhD
- Phone Number: +886-2-33668155
- Email: yayunlee@ntu.edu.tw
Study Contact Backup
- Name: DE-JUN LIM, Bachelor
- Phone Number: +886-9-66716146
- Email: R11428011@ntu.edu.tw
Study Locations
-
-
-
Taipei, Taiwan, 100229
- Recruiting
- National Taiwan University Hospital
-
Contact:
- Ya-Yun Lee, PhD
- Phone Number: +886-2-33668155
- Email: yayunlee@ntu.edu.tw
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- age above 20-years-old
- able to follow instructions to perform the tasks (Montreal Cognitive Assessment ≥ 24)
- no surgery and injury in upper extremities in recent 6 months
Exclusion Criteria:
- other neurological disorders in addition to Parkinson's disease
- Parkinson's disease dementia
- symptom of severe tremor in upper extremities (score ≥ 3 in Question 15 to 18 of UPDRS-III)
- deep brain stimulation or pacemaker implanted
- medical history of seizure
- a blood-relative with history of epilepsy
- unstable medical conditions
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Self-control group
Participants will be able to choose over feedback schedule when practicing finger-pressing trajectory matching task.
|
The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
|
|
Active Comparator: Yoked group
Participants will receive feedback, which was determined by their counterpart in self-control group, with no-choice when practicing finger-pressing trajectory matching task.
|
Learners practice the motor task, while the feedback is provided according to their counterpartner
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Performance accuracy
Time Frame: up to day 7
|
Overall performance accuracy relative to the target waveform was assessed using root mean square error (RMSE), which is the mean difference between the target waveform and the participant's movement trajectory calculated over their actual movement time.
|
up to day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intrinsic Motivation Inventory
Time Frame: day 1, day 2, day 7
|
A questionnaire with subscales of perceived competence and autonomy.
Questions were either taken directly or modified from the IMI, regarding to the participants subjective motivation after completing their practice trials.
|
day 1, day 2, day 7
|
|
Error Estimation
Time Frame: day 2, day 7
|
Participants will be instructed to estimate their error in RMSE after completing each trial in retention and transfer test.
Error estimation is used to assess the cognitive processing of participants during the trials.
|
day 2, day 7
|
|
Cortical excitability changes
Time Frame: Baseline, day 2, day 7
|
Transcranial magnetic stimulation (TMS) device (The Magstim Company Ltd, Whitland, UK) will be used to determine the neurophysiological changes of corticomotor excitability before and after the acquisition phase.
|
Baseline, day 2, day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Carter MJ, Ste-Marie DM. Not all choices are created equal: Task-relevant choices enhance motor learning compared to task-irrelevant choices. Psychon Bull Rev. 2017 Dec;24(6):1879-1888. doi: 10.3758/s13423-017-1250-7.
- Chiviacowsky S, Wulf G, Lewthwaite R, Campos T. Motor learning benefits of self-controlled practice in persons with Parkinson's disease. Gait Posture. 2012 Apr;35(4):601-5. doi: 10.1016/j.gaitpost.2011.12.003. Epub 2011 Dec 30.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 21, 2023
Primary Completion (Actual)
July 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
July 17, 2023
First Submitted That Met QC Criteria
July 24, 2023
First Posted (Actual)
July 25, 2023
Study Record Updates
Last Update Posted (Actual)
November 18, 2025
Last Update Submitted That Met QC Criteria
November 16, 2025
Last Verified
November 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 202304047RINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterNot yet recruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
-
ProgenaBiomeWithdrawnParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
Clinical Trials on Autonomy supported learning
-
Gazi UniversityCompletedNursing Education | Video-Assisted | OSCE (Objective Structured Clinical Examination)Turkey
-
Karabuk UniversityNot yet recruitingAnxiety | Episiotomy | Midwifery | Clinical Competence
-
Wang ShalongCentral South UniversityCompletedMedical Education | Artificial Intelligence | Self-Directed LearningChina
-
USDA Grand Forks Human Nutrition Research CenterCompletedOverweight | Sedentary Lifestyle | ChildUnited States
-
Baskent UniversityRecruitingNursing Education | Breast Self-Examination | Artifical IntelligenceTurkey (Türkiye)
-
Centre Hospitalier Universitaire de NiceNot yet recruitingAging | Aging, HealthyFrance
-
McMaster UniversityOntario Ministry of Health and Long Term CareCompleted
-
Ohio UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Blood CenterCompleted
-
Rigshospitalet, DenmarkCompletedMalignant Female Reproductive System Neoplasm | Survivorship | Supportive Care | Follow-up | Psychosocial CircumstancesDenmark
-
Hospices Civils de LyonRecruiting